IMIDAZOLONYL QUINOLINES AND USE THEREOF AS KINASE ATM INHIBITORS Russian patent published in 2021 - IPC C07D471/04 A61K31/4375 A61P35/00 

FIELD: pharmaceuticals.

SUBSTANCE: invention relates to imidazolonyl quinoline compounds applicable for inhibiting kinase activity. Disclosed is a compound of formula (IV), in which Het¹ denotes pyrazolyl, which can be unsubstituted or mono-, di- or trisubstituted, independently from each other, by Hal or A; A in each case independently denotes a straight or branched alkyl containing 1, 2, 3, 4, 5 or 6 C atoms, where independently of each other, 1, 2, 3, 4 or 5 H atoms can be replaced by Hal; Hal is F, Cl, Br or I; HET is selected from 3-difluoromethoxy-5-fluoropyridin-4-yl, 3-fluoro-5-methoxypyridin-4-yl, 3-fluoro-5-fluoromethoxypyridin-4-yl, 3-fluoro-5-(trideuteromethoxy)pyridin- 4-yl, as well as its pharmaceutically acceptable salt, tautomer or stereoisomer. What is also presented is a pharmaceutical composition which inhibits the activity of ATM kinase, containing the disclosed compound.

EFFECT: technical result is provision of small molecules, which effectively and selectively inhibit, regulate and/or modulate signal transduction by means of ATM kinase.

4 cl, 4 tbl, 16 ex